Non-Eosinophilic Neutrophilic Asthma
Dr. Vicente Plaza Moral (PRINCIPAL INVESTIGATOR)
Hospital de la Santa Creu i Sant Pau (HSP)
Dra. Astrid Crespo Lessmann
Hospital de la Santa Creu i Sant Pau
Dra. Ana Lapuente Torrents
Hospital Mutua de Terrassa
Dr. Eder Mateus Medina
Institut de Recerca IIB Sant Pau. Barcelona
Dra. Elena Curto Sánchez
Hospital de la Santa Creu i Sant Pau. Barcelona
Dr. Jordi Giner Donaire
Hospital de la Santa Creu I Sant Pau. Barcelona
Dr. David Ramos Barbón
Hospital de la Santa Creu I Sant Pau. Barcelona
Dra. Silvia Vidal Alcorisa
Institut de Recerca IIB Sant Pau. Barcelona
Dr. Xavier Muñoz Gall
Hospital Universitari Vall d’Hebron. Barcelona
Dra. Mariana Mercedes Muñoz
Esquerre
Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat
Dr. Carles Sabadell Nieto
Hospital de Figueres/ Fundació Salut Empordà. Figueres
Dra. Concepción Cañete Ramos
Hospital General de l’Hospitalet/Consorci Sanitari Integral. L’Hospitalet de Llobregat
Dra. Benedicta Abeijon Insua
Hospital de Terrassa/Consorci Sanitari de Terrassa
Dra. Pilar Ausin Herrero
Hospital del Mar/Consorci Parc de Salut Mar. Barcelona
Dr. Joan Serra Batlles
Hospital Universitari de Vic/Consorci Hospitalari de Vic
Dra. Ebymar Arismendi
Hospital Clínic de Barcelona
Dr. Cesar Picado Vallés
Hospital Clínic de Barcelona
Dra. Rosa Mª del Campo Moreno
Instituto Ramón y Cajal de Investigación Sanitaria. Madrid
Dr. Gustavo Rodrigo
Hospital Central de las Fuerzas Armadas de Montevideo (Uruguay)
Neutrophilic asthma (NA) is the least known phenotype of asthma, causes severe illness and has no specific treatment. Research on neutrophilic mechanisms, new types of neutrophils (NEU) and bronchial microbioma can offer an opportunity for a better understanding of their pathogenesis.
OBJECTIVES: 1. To describe the clinical characteristics of the NA and its subtypes (substudy 1); 2. To characterize the NEUs associated with it and its subtypes (substudy 2); and 3. To identify its bronchial microbial flora, in particular its association with the immune response to Chlamydia Pneumoniae (substudy 3).
METHODS: prospective multicentric study involving 100 patients with severe asthma (GEMA/GINA criteria): 50 with non-neutrophilic asthma (<65% NEU in induced sputum (IS) and 50 with NA (>64% NEU in IS).
Substudy 1: clinical variables will be collected (evolution years, exacerbations, ACT, miniAQLQ), comorbidities (RGE, nasal polyposis, obesity, SAHS), pulmonary function (FEV1, FENO, TLC, VR, KCO), blood analysis (leukocyte formula, IgE, IgG Aspergillus), prick-test and thorax CT.
Substudy 2 (in IS and plasma): apoptotic index by culture of NEU and flow cytometry (Annexin-V-FITC), NEU phenotype by surface markers (CD177, CD16, CD66b, CD62L, CD11b, CD63, HLA-DR, CXCR2, CXCR4) with density gradient study and cytokine determination (IL-6 IL-8, IL-1, IL-22, IL-17) by ELISA.
Substudy 3: (in IS and plasma): bronchial microbioma by 16S rRNa PICRUSt and anti-Chlamydia Pneumoniae IgA by ELISA.